Population pharmacokinetics - I: Background, concepts, and models

被引:144
作者
Ette, EI
Williams, PJ
机构
[1] Vertex Pharmaceut Inc, Cambridge, MA 02139 USA
[2] Univ Pacific, Sch Pharm, Dept Pharm Practice, Stockton, CA USA
[3] Trials Design LLC, Stockton, CA USA
关键词
population pharmacokinetics;
D O I
10.1345/aph.1D374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To present and emphasize the background, foundations, utility, and conceptual underlying theory of the population pharmacokinetic (PPK) approach with an examination of the advantages when compared with other approaches of pharmacokinetic modeling. DATA SOURCES: Information on PPK was retrieved from a MEDLINE search (1979-June 2002) of literature and a bibliographic review of review articles and books. STUDY SELECTION AND DATA EXTRACTION: All articles identified from data sources were evaluated and relevant information was included in this review. DATA SYNTHESIS: PPK plays a pivotal role in developing dosing strategies for direct patient care and in drug development. PPK is valuable because it targets the patient group that will eventually receive the drug of interest, quantitates pharmacokinetic variability at several levels, and seeks to explain those sources of variability. CONCLUSIONS: PPK models have great utility and the applications are many. They are very different from single-subject pharmacokinetic models and therefore require different approaches to model development.
引用
收藏
页码:1702 / 1706
页数:5
相关论文
共 19 条
  • [1] Population pharmacokinetics of carboplatin in children
    Chatelut, E
    Boddy, AV
    Peng, B
    Rubie, H
    Lavit, M
    Dezeuze, A
    Pearson, ADJ
    Roche, H
    Robert, A
    Newell, DR
    Canal, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) : 436 - 443
  • [2] POTENTIAL OF POPULATION PHARMACOKINETICS TO REDUCE THE FREQUENCY OF BLOOD-SAMPLING REQUIRED FOR ESTIMATING KINETIC-PARAMETERS IN NEONATES
    COLLART, L
    BLASCHKE, TF
    BOUCHER, F
    PROBER, CG
    [J]. DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1992, 18 (1-2): : 71 - 80
  • [3] PHARMACOKINETIC STUDIES IN ELDERLY PEOPLE - ARE THEY NECESSARY
    CROME, P
    FLANAGAN, RJ
    [J]. CLINICAL PHARMACOKINETICS, 1994, 26 (04) : 243 - 247
  • [4] ETTE EI, 1997, POPULATION APPROACH, P271
  • [5] THE IMPORTANCE OF MODELING INTEROCCASION VARIABILITY IN POPULATION PHARMACOKINETIC ANALYSES
    KARLSSON, MO
    SHEINER, LB
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (06): : 735 - 750
  • [6] KELMAN AW, 1982, COMPUT PROG BIOMED, V14, P239, DOI 10.1016/0010-468X(82)90029-0
  • [7] PAI SM, 1995, J CLIN PHARM THER, V32, P164
  • [8] Role of population pharmacokinetics in drug development - A pharmaceutical industry perspective
    Samara, E
    Granneman, R
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (04) : 294 - 312
  • [9] BAYESIAN INDIVIDUALIZATION OF PHARMACOKINETICS - SIMPLE IMPLEMENTATION AND COMPARISON WITH NON-BAYESIAN METHODS
    SHEINER, LB
    BEAL, SL
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (12) : 1344 - 1348
  • [10] EVALUATION OF METHODS FOR ESTIMATING POPULATION PHARMACOKINETIC PARAMETERS .3. MONOEXPONENTIAL MODEL - ROUTINE CLINICAL PHARMACOKINETIC DATA
    SHEINER, LB
    BEAL, SL
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (03): : 303 - 319